Genomic Predictors for Recurrence Patterns of Hepatocellular Carcinoma: Model Derivation and Validation

Abstract

Background: Typically observed at 2 y after surgical resection, late recurrence is a major challenge in the management of hepatocellular carcinoma (HCC). We aimed to develop a genomic predictor that can identify patients at high risk for late recurrence and assess its clinical implications. Methods and Findings: Systematic analysis of gene expression data fromhuman liver undergoing hepatic injury and regeneration revealed a 233-gene signature that was significantly associated with late recurrence of HCC. Using this signature, we developed a prognostic predictor that can identify patients at high risk of late recurrence, and tested and validated the robustness of the predictor in patients (n=396) who underwent surgery between 1990 and 2011 at four centers (210 recurrences during a median of 3.7 y of follow-up). In multivariate analysis, this signature was the strongest risk factor for late recurrence (hazard ratio, 2.2; 95% confidence interval, 1.3–3.7; p= 0.002). In contrast, our previously developed tumor-derived 65-gene risk score was significantly associated with early recurrence (p= 0.005) but not with late recurrence (p =0.7). In multivariate analysis, the 65-gene risk score was the strongest risk factor for very early recurrence (,1 y after surgical resection) (hazard ratio, 1.7; 95% confidence interval, 1.1–2.6; p= 0.01). The potential significance of STAT3 activation in late recurrence was predicted by gene network analysis and validated later. We also developed and validated 4- and 20-gene predictors from the full 233-gene predictor. The main limitation of the study is that most of the patients in our study were hepatitis B virus–positive. Further investigations are needed to test our prediction models in patients with different etiologies of HCC, such as hepatitis C virus. Conclusions: Two independently developed predictors reflected well the differences between early and late recurrence of HCC at the molecular level and provided new biomarkers for risk stratification.